...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Basic & clinical pharmacology & toxicology. >Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori Helicobacter pylori infection
【24h】

Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori Helicobacter pylori infection

机译：注册药物包与Maastricht V /佛罗伦萨共识报告的相关性和幽门螺杆菌幽门螺杆菌幽门螺杆菌感染的国家治疗指南

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract High prevalence of Helicobacter pylori infection, the complexity for its treatment, poor correlation of registered drug packs or poor patient adherence to the treatment may contribute to antibiotic resistance and healthcare costs. The aim of the present study was to investigate whether registered drug packs are in accordance with European and national guidelines for H?pylori eradication with reference to the number of drug units. In this study, we considered treatment options for the management of H?pylori infection recommended by the Maastricht V/Florence Consensus Report and by national guidelines in the United Kingdom (UK), Croatia, Italy and Slovenia for adults. Drugs proposed by the guidelines were identified in national drug databases in July of 2019. When considering correlation for 10‐day treatment regimens, drug packs registered in Croatia could not be matched with recommendations for sequential therapies. A number of proposed treatments could not be matched due to small variety of drug packs in Croatia. Drug packs registered in the UK more often matched recommended 14‐day treatment regimens and national guidelines. With reference to European guidelines, 10‐day treatments could more frequently be matched in Italy and in Slovenia. Furthermore, results of this study indicate that there is smaller variety in drug pack sizes registered in Croatia and Slovenia when compared to UK and Italy. Considering poor correlation of drug packs with treatment guidelines for H?pylori , adherence to antimicrobial treatment and proper disposal of antimicrobials is warrant. Discussing adherence to antimicrobial treatment with patients should be introduced as a standard of patient care and education.
机译：摘要幽门螺杆菌感染的高患病率，其治疗的复杂性，注册药物包装或患者粘附不良对待治疗可能有助于抗生素抗性和医疗费用。本研究的目的是调查登记的药物包是否符合欧洲和国家的H？幽门螺杆菌的指南，参考药物单位的数量。在这项研究中，我们考虑了Maastricht v /佛罗伦萨共识报告的幽门螺杆菌的治疗方案，并通过英国（英国），克罗地亚，意大利和成年人斯洛文尼亚的国家指南。指南提出的药物于2019年7月在国家药物数据库中确定。考虑到为期10天治疗方案的相关性，克罗地亚注册的药物包不能与顺序疗法的建议相匹配。由于克罗地亚的各种药物包，许多拟议的治疗方法无法匹配。在英国注册的药物包更常见的是建议的14天治疗方案和国家指南。参考欧洲准则，10天的治疗在意大利和斯洛文尼亚更频繁地匹配。此外，该研究的结果表明，与英国和意大利相比，克罗地亚和斯洛文尼亚的药物包尺寸较小。考虑到药物包的相关性与H·幽门螺杆菌治疗指南的相关性差，依赖于抗微生物治疗和适当处理抗菌药物是值得的。应讨论患者抗菌治疗的抗菌治疗作为患者护理和教育标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号